EMD Serono competitors

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

Robert A. Bradway is an American businessman. He is the chairman and chief executive officer of Amgen.

Chaim Lebovits has been at the forefront of mining and natural resource management in African regions for over a decade. He has spent years leading the exploration and development of resources in the Democratic Republic of Congo on behalf of world-leading firms. In this capacity, he has negotiated numerous, highly-successful deals on behalf of both African governments and global mining concerns. As an internationally known and respected business mogul and corporate manager, Lebovits has developed excellent personal relations with numerous African leaders, and has promoted the interests of their countries in the economic and political capitals of the world, both in official and unofficial capacities. Lebovits leads ACC HOLDINGS INTERNATIONAL and its many subsidiaries with his extensive experience and passion for the mining, oil, and energy industry, with intentions of taking ACC to a level of excellence and leadership in the resource mining sector. His commitment to the people that work with him, and to health, environmental and social issues, is evident in his projects in Africa. Lebovits into BrainStorm through ACCBT (ACC BioTech). ACCBT is one of ACC's subsidiaries that is totally focused on biotechnology. Originally from New York, Lebovits moved to Israel and now resides in Jerusalem. Lebovits has worked in senior positions for the worldwide Chabad Lubavitch organization and in the mining business, and launched his own private companies in 2005. Lebovits now splits his time between North America, Europe, Africa, and the Middle East.

Joe Turgeon is a President, COO at SPECTRUM PHARMACEUTICALS INC.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

Stephen Stamp is responsible for all financial matters at Assurex Health, including financing strategy and implementation, accounting, tax, mergers & acquisitions, and government contracting. Stephen brings to Assurex Health nearly 30 years of experience in finance, accounting, business development and operations. He has worked in multiple public and venture-backed companies both in the US and the UK, including business to consumer (B2C), business to business (B2B), and pharmaceutical industries. Stephen has served as Chief Financial Officer of EZCORP, Inc., a publicly-traded consumer financial services company; Chief Operating Officer, Chief Financial Officer, and Executive Vice President Business Development at Xanodyne Pharmaceuticals, Inc., a specialty pharmaceutical company; Group Finance Director at Regus PLC, a publicly-traded company that provides serviced office accommodations in business centers worldwide; and as Group Finance Director at Shire PLC, a publicly-traded UK specialty pharmaceutical company focused on ADHD and other specialty medications. Earlier in his career, Stephen was an investment banker with Lazard in London and worked for KPMG, also in London, where he qualified as a Chartered Accountant. Stephen received his BA in economics from the University of Manchester.